Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Sara Costi |
Documentos disponibles escritos por este autor (3)
Refinar búsquedaImpact of the kcnq2/3 channel opener ezogabine on reward circuit activity and clinical symptoms in depression / Laurel S. Morris en The American Journal of Psychiatry, Año 2021 - Vol. 178 - No.5 (Mayo)
Título : Impact of the kcnq2/3 channel opener ezogabine on reward circuit activity and clinical symptoms in depression : results from a randomized controlled trial Tipo de documento: texto impreso Autores: Laurel S. Morris, Autor ; Sara Costi, Autor ; Katherine A. Kirkwood, Autor Fecha de publicación: 2021 Artículo en la página: pp. 437-446 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Depresión, Antidepresivos, Anhedonia, Neuroimagen, Canal de potasio KCNQ Resumen: Preclinical studies point to the KCNQ2/3 potassium channel as a novel target for the treatment of depression and anhedonia, a reduced ability to experience pleasure. The authors conducted the first randomized placebo-controlled trial testing the effect of the KCNQ2/3 positive modulator ezogabine on reward circuit activity and clinical outcomes in patients with depression. Link: ./index.php?lvl=notice_display&id=26262
in The American Journal of Psychiatry > Año 2021 - Vol. 178 - No.5 (Mayo) . - pp. 437-446[artículo] Impact of the kcnq2/3 channel opener ezogabine on reward circuit activity and clinical symptoms in depression : results from a randomized controlled trial [texto impreso] / Laurel S. Morris, Autor ; Sara Costi, Autor ; Katherine A. Kirkwood, Autor . - 2021 . - pp. 437-446.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2021 - Vol. 178 - No.5 (Mayo) . - pp. 437-446
Palabras clave: Depresión, Antidepresivos, Anhedonia, Neuroimagen, Canal de potasio KCNQ Resumen: Preclinical studies point to the KCNQ2/3 potassium channel as a novel target for the treatment of depression and anhedonia, a reduced ability to experience pleasure. The authors conducted the first randomized placebo-controlled trial testing the effect of the KCNQ2/3 positive modulator ezogabine on reward circuit activity and clinical outcomes in patients with depression. Link: ./index.php?lvl=notice_display&id=26262
Título : A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder Tipo de documento: texto impreso Autores: Adriana Feder, Autor ; Sara Costi, Autor ; Sarah B. Rutter, Autor Fecha de publicación: 2021 Artículo en la página: pp. 193-202 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno de estrés postraumático, Ketamina, Midazolam, Trauma Resumen: Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors’ previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. Link: ./index.php?lvl=notice_display&id=26873
in The American Journal of Psychiatry > Año 2021 - Vol. 178 - No.2 (Febrero) . - pp. 193-202[artículo] A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder [texto impreso] / Adriana Feder, Autor ; Sara Costi, Autor ; Sarah B. Rutter, Autor . - 2021 . - pp. 193-202.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2021 - Vol. 178 - No.2 (Febrero) . - pp. 193-202
Palabras clave: Trastorno de estrés postraumático, Ketamina, Midazolam, Trauma Resumen: Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors’ previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. Link: ./index.php?lvl=notice_display&id=26873
Título : A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder Tipo de documento: texto impreso Autores: Adriana Feder, Autor ; Sara Costi, Autor ; Sarah B. Rutter, Autor Fecha de publicación: 2021 Artículo en la página: pp.193-202 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno de estrés postraumático, Ketamina, Midazolam, Trauma Resumen: Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors’ previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. Link: ./index.php?lvl=notice_display&id=26874
in The American Journal of Psychiatry > Año 2021 - Vol. 178 - No.2 (Febrero) . - pp.193-202[artículo] A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder [texto impreso] / Adriana Feder, Autor ; Sara Costi, Autor ; Sarah B. Rutter, Autor . - 2021 . - pp.193-202.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2021 - Vol. 178 - No.2 (Febrero) . - pp.193-202
Palabras clave: Trastorno de estrés postraumático, Ketamina, Midazolam, Trauma Resumen: Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors’ previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. Link: ./index.php?lvl=notice_display&id=26874
